Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Biosimilar Interleukins Market Over the Forecast Period of 2025 to 2034?

In recent times, the market size of biosimilar interleukins has witnessed a significant surge. The market is projected to expand from a worth of $3.9 billion in 2024 to about $5.41 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 39.0%. Factors contributing to this substantial increase during the historic period include the escalating occurrence of autoimmune diseases, heightened awareness about biosimilar interleukins, augmented government backing for biosimilars, the enlargement of the biosimilar market, and a rise in the patient demand for biosimilars.

The market for biosimilar interleukins is predicted to experience exceptional growth in the coming years, hitting $20.79 billion by 2029 with a compound annual growth rate (CAGR) of 40.0%. The anticipated growth during the forecast period stems from a rise in patient population, enhanced healthcare accessibility, an increasing demand for custom-tailored medicine, and a surge in the preference for minimally invasive procedures. Some of the predominant trends expected during this forecast period include the progression in biosimilar technology, targeted immunotherapies, stringent quality control and manufacturing processes, and extensive global collaboration.

What Are the Primary Drivers Supporting the Growth of the Biosimilar Interleukins Market?

The rise in autoimmune diseases such as psoriasis and rheumatoid arthritis is forecasted to stimulate growth in the interleukin biosimilars market. Autoimmune disorders, in which immune cells fail to differentiate between healthy cells and potentially hazardous antibodies, are becoming increasingly common. Biologic drugs like anti-interleukin antibodies have proven to be highly beneficial in controlling cellular regulation, proliferation, activation, and migration. For example, as reported by the National Institutes of Health (NIH), a US-based biomedical research entity, in February 2024, there’s an estimated 19.1% annual increment in global incidence and a 12.5% growth in autoimmune diseases prevalence. Therefore, the rising occurrence of autoimmune diseases is escalating the demand for biosimilar interleukins in the market, which is likely to propel market growth.

Explore Comprehensive Insights Into The Global Biosimilar Interleukins Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Biosimilar Interleukins Market?

Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

What Are the Latest Innovations and Trends Influencing the Biosimilar Interleukins Market?

Key players in the biosimilar interleukins market are focusing on new product innovations like Tofidence (tocilizumab-bavi), in a bid to enhance their market profitability. Tofidence, a monoclonal antibody, targets and binds to interleukin-6 receptors and is used for treating a range of inflammatory autoimmune disorders. For example, in September 2023, Tofidence obtained FDA approval as the premiere biosimilar to Genentech’s Actemra (tocilizumab), courtesy of Biogen, a biotech firm based in the US. Tofidence, which is delivered through an intravenous drip, has earned approval for managing severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Secure Your Global Biosimilar Interleukins Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

How Are Key Segments Defining the Competitive Landscape of the Biosimilar Interleukins Market?

The biosimilar interleukins market covered in this report is segmented –

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6

2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:

1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management

2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment

3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders

4) By IL-5: Asthma Treatment, Eosinophilic Disorders

5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

Which Geographical Regions Are Pioneering Growth in the Biosimilar Interleukins Market?

The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

How Do Experts Define the Scope of the Biosimilar Interleukins Market?

Biosimilar interleukins are defined as biosimilars produced by the body’s leukocytes (white blood cells). Immune reactions are controlled by interleukins. Laboratory-produced interleukins are used as biological response modifiers to strengthen the immune system in cancer treatment.

Browse Through More Similar Reports By The Business Research Company:

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market

Biosimilar Therapeutic Peptides Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: